133 related articles for article (PubMed ID: 38777140)
1. A Cost Effectiveness Analysis of Avacincaptad Pegol for the Treatment of Geographic Atrophy with Comparison to Pegcetacoplan.
Patel NA; Hoyek S; Al-Khersan H; Yannuzzi NA; Smiddy WE
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38777140
[TBL] [Abstract][Full Text] [Related]
2. A Cost-Effectiveness Analysis of Pegcetacoplan for the Treatment of Geographic Atrophy.
Patel NA; Al-Khersan H; Yannuzzi NA; Lin J; Smiddy WE
Ophthalmol Retina; 2024 Jan; 8(1):25-31. PubMed ID: 37572871
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibitors for age-related macular degeneration.
Tzoumas N; Riding G; Williams MA; Steel DH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
[TBL] [Abstract][Full Text] [Related]
4. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ; Khanani AM; Kaiser PK; Chang MA; Kovach JL; Lally DR; Rachitskaya A; Sheth VS; Vajzovic L; Clark J; Tang J; Zhu L; Desai D; Chakravarthy U
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38719191
[TBL] [Abstract][Full Text] [Related]
5. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ; Bagga P; Naik G; Glinton S; Faes L; Liefers B; Lima R; Wignall G; Keane PA; Ioannidou E; Ribeiro Reis AP; McKeown A; Scheibler L; Patel PJ; Moghul I; Pontikos N; Balaskas K
JAMA Ophthalmol; 2024 Jun; 142(6):548-558. PubMed ID: 38722644
[TBL] [Abstract][Full Text] [Related]
6. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
7. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
8. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
9. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM; Patel SS; Staurenghi G; Tadayoni R; Danzig CJ; Eichenbaum DA; Hsu J; Wykoff CC; Heier JS; Lally DR; Monés J; Nielsen JS; Sheth VS; Kaiser PK; Clark J; Zhu L; Patel H; Tang J; Desai D; Jaffe GJ;
Lancet; 2023 Oct; 402(10411):1449-1458. PubMed ID: 37696275
[TBL] [Abstract][Full Text] [Related]
11. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
Steinle NC; Pearce I; Monés J; Metlapally R; Saroj N; Hamdani M; Ribeiro R; Rosenfeld PJ; Lad EM
Am J Ophthalmol; 2021 Jul; 227():116-124. PubMed ID: 33675755
[TBL] [Abstract][Full Text] [Related]
12. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning.
Vogl WD; Riedl S; Mai J; Reiter GS; Lachinov D; Bogunović H; Schmidt-Erfurth U
Ophthalmol Retina; 2023 Jan; 7(1):4-13. PubMed ID: 35948209
[TBL] [Abstract][Full Text] [Related]
13. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S
JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137
[TBL] [Abstract][Full Text] [Related]
14. Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies.
Jaffe GJ; Khanani AM
Immunotherapy; 2024 Mar; 16(4):205-221. PubMed ID: 38270081
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR; Bandello F; Souied E; Guymer RH; Garg SJ; Chen FK; Rich R; Holz FG; Patel SS; Kim K; López FJ;
Ophthalmol Retina; 2023 Jul; 7(7):573-585. PubMed ID: 36906177
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept Monotherapy versus Bevacizumab-First for Diabetic Macular Edema: A Cost Analysis Based on Diabetic Retinopathy Clinical Research Network Protocol AC Results.
Patel NA; Al-Khersan H; Yannuzzi NA; Lin J; Smiddy WE
Ophthalmol Retina; 2023 May; 7(5):413-419. PubMed ID: 36423893
[TBL] [Abstract][Full Text] [Related]
17. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
18. Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
Vakharia P; Eichenbaum D
Curr Opin Ophthalmol; 2024 May; 35(3):165-169. PubMed ID: 38421937
[TBL] [Abstract][Full Text] [Related]
19. Complement Inhibitors for Advanced Dry Age-Related Macular Degeneration (Geographic Atrophy): Some Light at the End of the Tunnel?
Cruz-Pimentel M; Wu L
J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568533
[TBL] [Abstract][Full Text] [Related]
20. Treatment of geographic atrophy: an update on data related to pegcetacoplan.
Patel SB; Heier JS; Chaudhary V; Wykoff CC
Curr Opin Ophthalmol; 2024 Jan; 35(1):64-72. PubMed ID: 37815317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
